IL-1β, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are Enriched upon Monocyte–Breast Cancer Cell Cocultivation in a Matrigel-Based Three-Dimensional System

Nancy Adriana Espinoza-Sánchez1,2†, Gloria Karina Chimal-Ramírez1†, Alejandra Mantilla3 and Ezequiel Moisés Fuentes-Pananá1*

1Unidad de Investigación en Virología y Cáncer, Hospital Infantil de México Federico Gómez, Ciudad de México, México,
2Programa de Doctorado en Ciencias Biomédicas, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México, 3Departamento de Patología, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México

Breast cancer remains the first cancer-related cause of death in women worldwide, particularly in developing countries in which most cases are diagnosed in late stages. Although most cancer studies are based in the genetic or epigenetic changes of the tumor cells, immune cells within the tumor stroma often cooperate with cancer progression. Particularly, monocytes are attracted to the tumor primary site in which they are differentiated into tumor-associated macrophages that facilitate tumor cell invasion and metastasis. In this study, we used three-dimensional cultures to form acini-like structures to analyze the inflammatory secretion profile of tumor cells individually or in co-culture with monocytes. Breast cancer cell lines and primary isolates from eight Mexican patients with breast cancer were used. We found high levels of RANTES/CCL5, MCP-1/CCL2, and G-CSF in the breast cancer individual cultures, supporting an important recruitment capacity of monocytes, but also of neutrophils. The co-cultures of the tumor cells and monocytes were significantly enriched with the potent pro-inflammatory cytokines interleukin (IL)-1β and IL-8, known to support malignant progression. We also found that the interaction of tumor cells with monocytes promoted high levels of matrix metalloproteinases (MMP)-1, MMP-2, and MMP-10. Our study supports that a key event for malignant progression is the recruitment of different immune cell populations, which help to sustain and enhance a chronic inflammatory microenvironment that highly favors tumor malignancy.

Keywords: breast cancer, monocytes, matrigel-based 3D culture, inflammation, IL-1β, IL-8, MMPs

Abbreviations: BrC, breast cancer; PC, primary cultures; PM, primary monocytes; UIVC-IDC or UIVC-NIDC, Unidad de Investigación en Virología y Cáncer- Invasive or Non-invasive ductal carcinoma; MMPs, matrix metalloproteinases; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; TAMs, tumor-associated macrophages; MDSCs, myeloid-derived suppressor cells; MUC-1, mucin 1 (or epithelial membrane antigen); EpCAM, epithelial cell adhesion molecule.
INTRODUCTION

Breast cancer (BrC) is the most common cancer and the main cause of cancer-related death in women worldwide. BrC greatly affects the quality of life of working-age women, and the likelihood of patients to present aggressive cancer features, such as metastasis, resistance to treatment, and disease relapse, remains high, particularly in developing countries in which BrC is diagnosed at advanced stages (1). Great efforts have been placed to grade BrC into clinical stages to try to improve the effectiveness of therapy schemes. However, tumor classification and directed therapies are based mainly on the genetic or epigenetic changes of the tumor cell itself (2). Today, we understand that tumors are formed by a variety of cells of different origins, the tumor stroma or tumor microenvironment, in which the tumor cell coexists with non-tumor cells, for instance fibroblasts, endothelial cells, and immune cells (3, 4). One of the main cell populations found in the stroma of many types of tumors are the macrophages, termed tumor-associated macrophages or TAMs (5, 6).

Increasing evidence supports that chronic inflammation deeply impacts cancer initiation and progression (7). Circulating monocytes are persistently chemotrafficked to inflammatory sites in which they differentiate into macrophages that help to maintain the inflammatory process, thus creating a positive loop. Macrophages were initially thought to exclusively perform immune defense functions, such as removal of invading pathogens and cancer cells, because of their potent phagocytic, oxygen-dependent intracellular killing and antigen-presenting activities. However, macrophages also participate in clearing of aging cells and tissue remodeling in non-pathological conditions and healing or tissue repair after pathological conditions. To do this, macrophages are highly plastic cells of which there are many subtypes expressing different sets of bioactive molecules that contribute to tissue growth through mechanisms of cell proliferation, angiogenesis, and immunosuppression (8–10). Since the pioneering studies by Lin et al. using murine BrC models, it was clear that preventing the arrival of monocytes into the tumor site resulted in small tumors and decreased metastases (11). Today, there is evidence supporting that TAMs have crucial roles in angiogenesis, invasion, and metastasis, and a dense infiltration of these cells into human primary tumors is significantly associated with poor prognosis (12, 13). Both inflammatory and anti-inflammatory macrophages can potentially cooperate with tumor evolution.

To study the communication that tumor cells establish with monocytes, we have previously used aggressive (MDA-MB-231) and non-aggressive (MCF-7) BrC cell lines co-cultured with the monocytic cell line U937 in a Matrigel-based three-dimensional (3D) system, finding that U937 cells significantly upregulate expression of matrix metalloproteinases (MMPs) and inflammatory mediators in response to soluble factors from the most aggressive BrC cells (14). To follow up those findings, we decided to test primary tumor cells obtained from BrC patients and analyze their secretion profiles, both individually and in co-culture with primary monocytes (PM) and monocytic cell lines. We think that working with primary isolates we would obtain information that more closely reflected the biology of the tumors. We found that primary BrC cells are secreting high levels of the chemokines RANTES/CCL5, MCP-1/CCL2, and G-CSF, which revealed their potential capability to recruit and activate monocytes. When BrC cells were co-cultured with monocytes, we observed a significant increased secretion of interleukin (IL)-1β and IL-8, two interleukins associated with malignant progression of several types of cancer. Interestingly, IL-1β and IL-8 also distinguished co-cultures of aggressive from non-aggressive BrC cell lines. Finally, we also observed increased levels of MMP-1, MMP-2, and MMP-10 in co-cultures. This study supports the idea that the potential of aggressiveness of BrC cells is given by their ability to recruit monocytes and to instruct them to secrete high levels of potent pro-inflammatory cytokines IL-1β and IL-8, and metalloproteinases MMP-1, MMP-2, and MMP-10. These mechanisms may favor tumor progression contributing with recruitment of other immune cells and facilitating cell invasion and metastasis.

MATERIALS AND METHODS

Patient Recruitment and Primary Cell Isolation

Patient samples were obtained from the tissue bank of the Unidad de Investigación en Virología y Cáncer, Hospital Infantil de México Federico Gómez, for which patients signed an informed consent, and the protocol was approved by the Scientific, Ethics, and Biosafety Institutional Review Boards. Tumor samples were taken from patients diagnosed with ductal carcinoma and with no previous neoadjuvant therapy before tissue resection.

The tumor tissue was rinsed with PBS and mechanically disaggregated with a scalpel in 1–2 mm fragments, which were subsequently digested for 2 h at room temperature (RT) with a mixture of 1 mg/mL collagenase type I and 100 U/mL hyaluronidase (both from Sigma; Saint Louis, MO, USA) in DMEM/F12 containing 100 U/mL penicillin and 100 μg/mL streptomycin, in constant stirring. The resulting suspension was filtered through a wide pore membrane and subsequently in a 100 μm pore membrane. The cells were pelleted and washed twice with sterile PBS and finally placed in their culture media. Cell morphology of primary isolates was analyzed and compared to the morphology of the commercial BrC cell lines in 2D (monolayer) and 3D culture conditions. Images were taken with an Olympus BX-41 microscope (Olympus Corporation, Tokyo, Japan). Primary cultures (PC) were given consecutive numbers; of 16 tumor tissues plated, eight PC were established for at least seven passages. These cultures were named UIVC-IDC-1, -4, -5, -6, -9, -10, -11, and UIVC-NIDC-1.

Cell Culture

All commercial cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and culture media and supplements from Gibco Invitrogen Cell Culture (Carlsbad, CA, USA) unless specified differently. The human monocytic cell lines THP-1 (No. TIB-202), U937 (No. CRL-1593.2), and the BrC line T47D (HTB-133) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 U/mL streptomycin, at 37°C in 5% CO₂. BrC
cells MCF-7 (No. HTB-22) and MDA-MB-231 (No. HTB-26) were cultured in DMEM/F12 medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin, at 37°C in 5% CO₂. BrC cells HS578T (No. HTB-126) were cultured in high glucose (4.5 g/L) DMEM medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin, at 37°C in 5% CO₂. MCF-10A cells (No. CRL-10317) were cultured in DMEM/F-12 medium supplemented with 20 ng/mL of epidermal growth factor (EGF; PeproTech, Rocky Hill, NJ, USA), 10 μg/mL insulin, 0.5 μg/mL hydrocortisone, 100 ng/mL chola toxin (all from Sigma Chemical Co., St. Louis, MO, USA), 5% horse serum, 100 U/mL penicillin and 100 μg/mL streptomycin. Primary tumor cell isolates were cultured in DMEM/F12 supplemented with 5% horse serum, 100 U/mL penicillin and 100 μg/mL streptomycin, 100 ng/mL chola toxin, 0.5 μg/mL hydrocortisone, 10 μg/mL insulin, and 20 ng/mL of EGF at 37°C in 5% CO₂ atmosphere.

Isolation of Peripheral Blood PM
Peripheral blood mononuclear cells (PBMCs) were isolated according to the following protocol: 40 mL of blood of healthy volunteers was extracted, diluted in a 1:3 proportion with sterile endotoxin-free PBS (Gibco Invitrogen Cell Culture), and subjected to density gradient centrifugation with Histopaque®-1077 (Sigma-Aldrich Inc., St. Louis, MO, USA) per 30 min at 2,000 rpm. PBMCs were then carefully retrieved from the gradient and washed three times with PBS, each time followed by slower centrifugation (1,500, 1,250, and 1,000 rpm). To obtain the monocyte-enriched fraction, PBMCs were subjected to negative selection with the Monocyte Isolation Kit II Human (Miltenyi Biotec Inc., Auburn, CA, USA) following the manufacturer’s recommendations as we briefly describe next. PBMCs were washed once with diluted 1:20 MACS BSA Stock Solution (Miltenyi Biotec Inc., Auburn, CA, USA), counted, and adjusted to a density of 10^7 cells per 30 μL of buffered solution; 10 μL of FcR-blocking reagent and 10 μL of monocyte biotin-antibody cocktail were then added for every 10^7 cells to be labeled; cells were mixed and incubated for 15 min at 4°C. An additional 30 μL of buffered solution was added plus 20 μL of anti-biotin microbeads for every 10^7 cells to be labeled; cells were mixed and incubated for 20 min at 4°C. Cells were then washed once with buffered solution, centrifuged at 1,500 rpm for 5 min, and resuspended in 1.5 mL of buffered solution for magnetic separation. Suspension of cells was passed through a pre-rinsed LS column (Miltenyi Biotec Inc., Auburn, CA, USA) and 7 mL of buffered solution was added. The monocyte-enriched cells were collected in a conical 15 mL tube, counted, and if not cultured immediately, monocytes were frozen at a density of 2 × 10^7 in 1 mL of DMEM/F12 medium supplemented with 50% FBS and 10% DMSO at −80°C. PM used for experimentation were never frozen for more than 2 months after isolation. Cultures were maintained in DMEM/F12 medium supplemented with 6% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin, at 37°C in 5% CO₂ atmosphere. Each set of experiments was performed utilizing PM of at least two different donors (each donor isolates independently because pooling resulted in monocyte activation). The phenotype of purified monocytes was very homogeneous between different isolates: CD34<sup>-</sup>CD11b<sup>+</sup>CD14<sup>+</sup>CD64<sup>+</sup>CD68<sup>+</sup>CD16<sup>+</sup>, and also with both monocytic cell lines, which corresponds to the phenotype of a non-activated immature monocyte (15).

Immunocytochemistry of Epithelial Markers
A total of 20,000 cells of the primary isolates were plated on 8-well chamber slides (Nunc<sup>®</sup> Lab-Tek<sup>®</sup> Chamber Slide System, Sigma), cultured for 48 h in their correspondent media, rinsed with PBS, and fixed with paraformaldehyde at RT for 10 min. Cells were then hydrated with PBS and permeabilized with 0.05% triton X-100 for 10 min at 4°C. Endogenous peroxidase activity was blocked by incubating the slides in peroxidase blocking solution (Dako, Inc., Carpinteria, CA, USA). Non-specific antibody binding was blocked by incubation with 8% albumin in PBS for 20 min. The slides were incubated with the following primary antibodies at an optimized concentration: mouse monoclonal anti-human anti-PanCytokeratin (Clone AE1/AE3; Biocare Medical; Concord, CA, USA), mouse monoclonal anti-human anti-mucin 1 (MUC-1) [epithelial membrane antigen (EMA; Clone Mc-5; Biocare Medical)], and mouse monoclonal anti-human anti-epithelial cell adhesion molecule (EpCAM, clone AA1; Biocare Medical). Cells were incubated overnight in a moist chamber at 4°C. The EnVision Detection Kit (Dako; Carpinteria, CA, USA) was employed as the detection system. Cells were counterstained with hematoxinil for 5 min followed by 5 min 0.9% ammonium hydroxide at RT, rinsed with distilled water, and left to dry at RT and permanently cover slipped. Slides were analyzed and photographed with an Olympus BX-41 microscope (Olympus Corporation, Tokyo, Japan).

Primary Culture Growth in Medium of Mesenchymal Cell
4 × 10<sup>5</sup> cells from primary isolates were seeded in 4 mL of low glucose (1 g/L) DMEM medium (Gibco Invitrogen), with sodium pyruvate 110 mg/L, without HEPES and supplemented with 15% FBS, 1% l-glutamine, and 100 U/mL penicillin and 100 μg/mL streptomycin and incubated at 37°C in 5% CO₂. Cells were maintained for 5–7 days in the described conditions and their growth evaluated. Results were scored as none when no growth was observed, one cross when cells attached and formed ≈40% of a confluent layer, two crosses 80–90% of confluence, and three crosses when cells were passaged and proliferate in a new culture flask with mesenchymal cell medium. Bone marrow mesenchymal cells were used as positive control and MCF-10A cells as negative control.

3D Culture and Harvest of Cell Culture Supernatants
For 3D individual cultures, a 40 μL base of Matrigel was added per well of an 8-well chamber slide system (8-well plates, Lab-Tek Chamber Slide System, Nalgene Nunc International, Rochester, NY, USA), incubated for 30 min at 37°C and 800 cells were added in 400 μL of the correspondent culture medium supplemented with 4 ng/mL of EGF and 2% Matrigel. For 3D co-cultures, 4 × 10<sup>5</sup> monocytes contained in 1 mL of their correspondent medium supplemented with 2% Matrigel and 2% FBS for U937.
and THP-1 monocytes, or 2% Matrigel and 6% FBS for PM, were plated per well of a 24-well flat-bottom culture plate. A transwell cell culture insert with pore size of 0.4 μm (Thermo Fisher Scientific™ Nunc™; Waltham, MA, USA) was placed in each well containing 1 mL of a 4 × 10^5 BrC cells in their corresponding medium supplemented with 2% Matrigel and 2% FBS (for commercial cell lines) or 5% horse serum for PC. Controls of individual cell cultures with the same media were included. After 5 days of culture, the supernatants from bottoms and tops of the 3D co-cultures were recovered, mixed, aliquoted, and kept at −20°C until use.

### Analysis of Cytokine Profiles

The following analytes were determined in the supernatants of the cultures: granulocyte-colony-stimulating factor (G-CSF), granulocyte-macrophage-colony-stimulating factor (GM-CSF), interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17, interferon-alpha 2 (INF-α2), monocyte chemoattractant protein-1 (MCP-1) also known as chemokine CCL2, regulated on activation normal T cell expressed and secreted (RANTES) also known as chemokine CCL5, EGF, vascular endothelial growth factor (VEGF), and a panel of the MMP-1, -2, -7, -9, and -10. The determinations were done with the multiplexing assay platform from MILLIPLEX (EMD Millipore Corporation, Billerica, MA, USA) following the manufacturer's recommended procedure. Briefly, in each well of a 96-well flat-bottom culture plate 25 μL of assay buffer was mixed with 25 μL of supernatants or controls and 25 μL of the detection microbeads cocktail. The mixture was incubated at 4°C overnight with orbital agitation. Wells were then washed twice with washing buffer, 25 μL of the detection antibodies mix was added to each well, and the plate was incubated at RT with orbital agitation for 1 h. After incubation, 25 μL of streptavidin-phycocerythrin was added to each well followed by 30 more minutes of incubation at RT with orbital agitation. The wells were then washed twice with washing buffer, 150 μL of PBS was added to each well to proceed with the analysis in Luminex MAGPIX multiplexing instrument, and the analysis of data was performed in the xPONENT® Software. Three biological replicates were analyzed.

### Migration and Invasion Assays

Migration assays with U937, THP-1, and fresh PM were performed in 24-well plates using polycarbonate membrane transwell inserts with 8-μm pores (Corning Costar, USA) filled with Matrigel. 1.5 × 10^5 monocytes were resuspended in 200 μL of RPMI without serum and placed in the upper chamber. Then, transwells were placed in a 24-well culture dish containing 800 μL of RPMI without serum but supplemented with either 100 ng/mL of GM-CSF, MCP-1, or RANTES (all from PeproTech, Rocky Hill, NJ, USA) that was used as chemoattractant. Cell migration was allowed to progress for 24 h at 37°C in a humidified 5% CO₂ environment. The migrating cells were counted at 2, 4, 6, and 24 h using a microscope Motic AE31, and images were acquired with a digital camera (Moticam 5.0 MP). The mean cell count from three random fields (at 100X magnification) was used for the analysis. The BrC cell lines invasion assays, a total of 6 × 10^5 cells were resuspended in 200 μL of their respective media without sera and placed in the upper chamber of the Transwell filled with Matrigel (as for the monocytes). The Transwells were placed in a 24-well culture dish containing 800 μL of their respective media with sera or without sera but supplemented with 100 ng/mL of IL-8 as chemotaxtractant (PeproTech, Rocky Hill, NJ, USA). The experiment proceeded as for monocytes and after 48 h, invading cells were stained with crystal violet and observed under the microscope. The mean cell count from three random fields (at 100X magnification) was used for the analysis of Figure 6C and the integrated optical density (IOD) for the analysis of Figure S1 in Supplementary Material. Three biological replicates were performed.

### Immunofluorescence Assay

3 × 10^4 cells of each of the cell lines were seeded on coverslips for 24 h in their respective media. Then, cells were fixed with 4% paraformaldehyde for 10 min, and permeabilized with 0.2% Triton X-100 in PBS for 20 min. Cells were blocked with blocking buffer (10% goat serum, 0.2% triton X-100, and PBS 1X) for 1 h and then stained with the primary antibodies: mouse monoclonal anti-E-Cadherin antibody (Clone: 36/E-cadherin; BD Biosciences, San José, CA, USA), rabbit monoclonal anti-Vimentin antibody-Alexa Fluor-594 (Clone: EPR3776; Abcam, Cambridge, MA, USA), overnight at 4°C. After that, cells were incubated with the secondary antibody goat anti-mouse-IgG-FITC antibody (Sigma-Aldrich Co., St. Louis, MO, USA) for 30 min. Nuclei were stained with DAPI for 25 min. Cells were observed using a fluorescence microscope Olympus BX51, and images were acquired with a digital camera (Camedia C4040, Olympus).

### Statistical Analysis

Statistical comparison of values from the different conditions tested was performed with the GraphPad Prism 5 Software, using Kruskal–Wallis test and Mann–Whitney test to compare all data columns. Statistical significance (p) ≤ 0.05 was indicated with *, ≤0.01 was indicated with **, and ≤0.001 with ***.

### RESULTS

#### Aggressive Breast Cancer Cells Establish a Microenvironment Enriched with IL-1β and IL-8

We have previously generated evidence that aggressive BrC cells modulate the expression of monocytes to favor conditions for tumor invasion (14). We define the aggressive potential of BrC cells as follows: to present a cancer stem cell-like phenotype CD44+ CD24−low, to present the epithelial-to-mesenchymal transition (EMT), which is characterized by positivity to vimentin (mesenchymal marker) and negativity to E-cadherin (epithelial marker), and to be invasive in transwell assays. According to these characteristics, MCF-7 and T47D cells were classified as non-aggressive and MDA-MB-231 and HS578T cells as aggressive. This characterization correlates with the ability of MDA-MB-231 and HS578T cells, but no of MCF-7 and T47D cells, to form metastasis in immunodeficient mice (16–19). To extend our
initial observations, we used three different types of monocytes: commercial U937 and THP1 monocytes, which were obtained from patients with diffuse histiocytic lymphomas and have been widely used as models of macrophage differentiation (20–23), and PM isolated from healthy donors. All the different monocytes presented an immature non-activated phenotype (15).

The co-cultures with the commercial BrC cell lines and monocytes were done in a Matrigel 3D matrix, after which the content of several cytokines, chemokines, and growth factors (G-CSF, GM-CSF, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17, INF-α2, MCP-1, RANTES, EGF, and VEGF) were measured in the supernatants. Consistent readings were obtained for the following analytes: RANTES, MCP-1, G-CSF, GM-CSF, IL-8, IL-1β, INF-α2, and IL-12p70, all related to inflammatory processes, although only the first six have been previously associated with pro-tumor effects. Figure 1A shows three independent assays of the three types of monocytes in co-culture with the commercial BrC cells. It can be observed that IL-1β and IL-8 levels were increased upon co-culture, while the opposite happened with INF-α2 and IL-12p70, which presented the highest levels in some of the monocytes cultured individually. The most relevant result observed was that of IL-1β and IL-8 (Figure 1B). In the case of IL-1β, we found statistical differences between co-cultures and individual cultures. Interestingly, the concentration of IL-1β also allowed distinguishing between co-cultures of the most aggressive BrC cells (average of 183.7 pg/mL) and the non-aggressive cells (94.0 pg/mL). Similarly, IL-8 basal levels (3D) perfectly segregate non-aggressive (average of 30.83 pg/mL) from aggressive tumor cells (average of 9,654 pg/mL). Also, the levels of IL-8 increased significantly when non-aggressive tumor cells were co-cultured with monocytes (average of 6,737 pg/mL), although we did not observe a significant difference between co-cultures of the BrC aggressive cells and co-cultures of the non-aggressive cells.

Clinical Characteristics of Breast Cancer Patients and Morphology of Cell Isolates in Culture

To extend these observations, the experiments were repeated using primary tumor cells isolated from BrC Mexican patients. The tumor cells were derived from eight female patients with an average age of 56.8 years (range 42–75). All tumors were classified as ductal, with seven out of eight already showing tissue infiltration and three patients already presenting lymph node involvement. Seven tumors were classified as histological grade II and one as grade III, and seven were clinical stages IIA or IIB in infiltration and three patients already presenting lymph node involvement. Seven tumors were classified as histological grade II and one as grade III, and seven were clinical stages IIA or IIB. All tumors were classified as ductal, with seven out of eight already showing tissue infiltration and three patients already presenting lymph node involvement. Seven tumors were classified as histological grade II and one as grade III, and seven were clinical stages IIA or IIB (Table 1).

For the duration of this study, PC were maintained for up to seven passages in mammary epithelial cell growth medium. We determined their identity as epithelial cells after positive staining to three well known epithelial markers: a panel of cytokeratins, mucin 1, and EpCAM (Figure 2A; Table 2). The primary tumor cells expanded in epithelial cell growth medium were also plated in medium specialized to grow mesenchymal cells, we thought that this was important to exclude the possibility of culture contamination with other resident cells of the tumor stroma that could have pro-tumoral activities. We found that cultures UIVC-IDC-1, -4, -6 and UIVC-NIDC-1 proliferated to different extents in mesenchymal medium (Figure 2B; Table 2). However, cells recovered after expansion in this medium still were positive for epithelial markers (Figure 2C).

We concluded that cells expanding in this medium were not mesenchymal cells contaminating the primary isolates, but rather that these tumor epithelial cells acquired mesenchymal characteristics that allowed them to adapt to mesenchymal culture conditions. MCF-10A non-transformed cells were unable to expand in mesenchymal medium (not shown).

Co-cultures of Primary Breast Cancer Isolates and Monocytes Are Also Enriched with IL-1β and IL-8

We co-cultured the primary BrC isolates with the PM. The results showed that MCP-1, G-CSF, RANTES, GM-CSF, INF-α2, and IL12-p70 analytes gave no differences between the 3D individual cultures and the 3D co-cultures (data not shown). However, IL-1β and IL-8, which in commercial lines allowed to distinguish between aggressive and non-aggressive BrC cells, showed again a significant increased concentration in co-culture (Figure 4). IL-1β increased from 3.3 pg/mL (individual 3D culture) to 16.5 pg/mL (co-culture), while IL-8 increased from 8,886.3 pg/mL (3D) to 12,027.4 pg/mL (CC).

MMP-1, MMP-2, and MMP-10 Are Induced in Breast Cancer Primary Cells/Monocytes Co-Cultures

Our initial findings also support that aggressive MDA-MB-231 cells promote secretion of MMPs in co-culture with U937 monocytes (14). To extend those results, we analyzed the levels of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 present in the primary isolates individually cultured or co-cultured with PM. We did not find significant differences in the secretion levels...
FIGURE 1 | Levels of inflammatory cytokines present in supernatants of commercial breast cancer (BrC) cell lines in co-culture with monocytes. Inflammatory cytokines were determined in three-dimensional (3D) individual cultures of the BrC cell lines (indicated as 3D) and in co-culture with the three different sources of monocytes independently [THP-1, U937, and primary monocytes (PM); indicated as cells co-cultured (CC)]. (A) The means and SD of three independent co-culture experiments are shown (in picogram/milliliter). (B) Summary of the cytokines that gave statistically significant differences. For the statistical analysis, MCF-7 and T47D cells were grouped as non-aggressive BrC cells and MDA-MB-231 and HS578T were grouped as aggressive BrC cells. THP-1, U937, and PM were grouped as Monocytes, and statistics were calculated using all combinations of aggressive vs non-aggressive BrC cells with all the types of monocytes. Left panel [interleukin (IL)-1β]: statistical differences were found between BrC cells cultured individually vs in co-culture with monocytes, and between co-cultures of the non-aggressive BrC cells vs the co-cultures of the aggressive cells. Right panel (IL-8): statistical differences were found between non-aggressive cells cultured individually (3D) and the rest of the groups: non-aggressive CC with monocytes and with aggressive cells either cultured individually or in co-culture with monocytes. Statistical significance $p \leq 0.05$ was indicated with *, $p \leq 0.01$ with **, and $p \leq 0.001$ with ***. The statistical tests comparing monocytes against co-cultures showed significant differences only for HA-BrC (IL-1β $p = 0.0001$ and IL-8 $p = 0.0014$) but not for NA-BrC cells (IL-1β $p = 0.752$ and IL-8 $p = 0.0942$).
only primary isolate secreting detectable levels of MMP-9. More interestingly, MMP-1, MMP-2, and MMP-10 showed significant differences between co-cultures and individual 3D cultures (Figure 5). In the case of MMP-1 and -2, the basal levels in individual cultures were average of 19.264 pg/mL (MMP-1) and of 12,474 pg/mL (MMP-2), which in co-culture with monocytes was further increased 3- and 1.9-fold, respectively. For MMP-10, the average level found in supernatants from individual cultures was of 219.3 pg/mL and in the co-cultures with monocytes increased 2.6-fold.

**Primary Breast Cancer Cultures Exhibit an Inflammatory Secretion Profile Rich in Chemotactic Cytokines**

In an attempt to understand the cytokine profile of tumor cells that promote an immunological shift or immunoediting in monocytes (24), we analyzed the basal expression levels of the commercial and primary BrC cells (Figure 6A). We found an interesting inflammatory profile promoted by the PC, which consisted of high concentrations of MCP-1/CCL2 (average of 9,277.09 pg/mL), G-CSF/SDF3 (average of 3,999.37 pg/mL) and RANTES (average of 953.19 pg/mL) and, lower levels of INF-α2 (average of 27.07 pg/mL) and IL-12p70 (average of 6.415 pg/mL). For GM-CSF, two cultures were polarized from the rest, UIVC-IDC-1 had 5,022.8 pg/mL and UIVC-IDC-9 had 573.6 pg/mL, the rest of

| Primary culture | Age | Histological subtype | Histological grade | TnM staging   | Clinical stage |
|-----------------|-----|----------------------|-------------------|--------------|---------------|
| UIVC-IDC-1      | 52  | IDC                  | 2                 | T1N0M0 I     |               |
| UIVC-IDC-4      | 63  | IDC                  | 2                 | T1N1M0 IIA   |               |
| UIVC-IDC-5      | 75  | IDC                  | 2                 | T2N0M0 IIA   |               |
| UIVC-IDC-6      | 55  | IDC                  | 2                 | T1N0M0 IIA   |               |
| UIVC-NIDC-1     | 56  | DCIS                 | 2                 | T1N0M0 IIA   |               |
| UIVC-IDC-9      | 42  | IDC                  | 2                 | T2N1M0 IIB   |               |
| UIVC-IDC-10     | 64  | IDC                  | 3                 | T3N0M0 IIB   |               |
| UIVC-IDC-11     | 48  | IDC                  | 2                 | T2N1M0 IIB   |               |

IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ.

**TABLE 1 | Clinical characteristics of breast cancer patients.**

![Image of epithelial markers in breast cancer primary cell cultures](image)

**FIGURE 2 | Epithelial markers in breast cancer primary cell cultures.** (A) Representative images of epithelial markers (PanCytokeratin, Muc-1/epithelial membrane antigen, and EpCAM) in three primary cultures (PC) determined by immunocytochemistry. Non-transformed MCF-10A breast epithelial cells were used as positive and U937 monocytes as negative staining controls. (B) Representative images of PC UIVC-IDC-1, -4, and -6 proliferating in mesenchymal medium (magnification 100x). (C) Epithelial markers determined by immunocytochemistry in UIVC-IDC-6 after one passage in mesenchymal medium. Scale bars correspond to 100 μm, magnification 200x.
TABLE 2 | Characterization of breast cancer primary cultures.

| Primary culture | Epithelial markers | Proliferation in epithelial medium | Proliferation in mesenchymal medium | Growth (2D) | Growth three-dimensional | EMT | Invasion |
|-----------------|-------------------|----------------------------------|------------------------------------|-------------|--------------------------|-----|---------|
| UIVC-IDC-1      | Pos               | Pos                              | ++                                 | Aggressive  | Aggressive               | ND  | ND      |
| UIVC-IDC-4      | Pos               | Pos                              | ++                                 | Aggressive  | Aggressive               | ND  | ND      |
| UIVC-IDC-5      | Pos               | Pos                              | None                               | Non-aggressive | Aggressive | ND  | ND      |
| UIVC-NIDC-1     | Pos               | Pos                              | +                                  | Aggressive  | Aggressive               | Pos  | Pos     |
| UIVC-IDC-9      | Pos               | Pos                              | None                               | Non-aggressive | Aggressive | Pos  | Pos     |
| UIVC-IDC-10     | Pos               | Pos                              | None                               | Non-aggressive | Aggressive | ND  | ND      |
| UIVC-IDC-11     | Pos               | Pos                              | None                               | Aggressive  | Aggressive               | ND  | ND      |

EMT, epithelial to mesenchymal transition; ND, non-determined; Pos, positive.

FIGURE 3 | 2D and three-dimensional (3D) growth of breast cancer (BrC) primary cultures (PC). (A) MCF-7 and T47D cobblestone-like growth was used as representative of cells with non-aggressive features, while MDA-MB-231 and HS678T spindle-like growth was used as representative of aggressive BrC cells. MCF-10A cells are included as the type of growth observed with non-transformed cells. Representative images of PC UIVC-IDC-5, UIVC-NIDC-1, and UIVC-IDC-10 in early passages, which displayed a very similar morphology to non-aggressive BrC cells, while the rest of the primary isolates showed a 2D morphology closer to the one found in aggressive cells. Scale bars correspond to 100 μm, magnification 200x. (B) Comparison of the 3D growth of primary isolates with commercial non-transformed, aggressive, or non-aggressive cell lines. Scale bars correspond to 50 μm, magnification 200x.

the primary isolates ranged from 4.5 to 51.2 pg/mL. Interestingly, this profile is in good correlation with the profile found in the commercial BrC cell lines, with aggressive cells exhibiting higher levels of MCP-1 and G-CSF, and GM-CSF appreciably separating aggressive from non-aggressive cells. On the contrary, primary and commercial BrC cells showed low levels of INF-α2 and IL-12p70 (Figure 6A). Other cytokines were either or both, not significantly different between aggressive and non-aggressive cells or they had no detectable levels, such as IL-2 and IL-4 (data not shown).

An important observation taken from this experiment was that the most enriched cytokines are critical monocyte chemo-attractants. Because of the increased secretion of MMPs, migration assays were performed with commercial and PM in response to GM-CSF, MCP-1, and RANTES in Matrigel filled Transwell inserts. We observed that U937 and THP-1 cells were capable to migrate in response to GM-CSF (average numbers of migrating cells/field were 115 for U937 and 11.5 for THP-1) and to MCP-1 (average numbers of migrating cells/field were 99.7 for U937 and 12.8 for THP-1) and low to null response to RANTES. PM
Figure 5 | Concentrations of MMP-1, MMP-2, and MMP-10 measured in supernatants significantly increased when primary cells derived from the eight BrC patients were co-cultured with the primary monocytes from healthy donors. Three independent experiments were carried out and each point represents the mean of all determinations for each BrC primary isolate. Statistical significance ($p \leq 0.05$) is indicated with *.

Figure 4 | Levels of interleukin (IL)-1β and IL-8 increased when primary breast cancer (BrC) cells were co-cultured with monocytes. Levels of IL-1β (left panel) and IL-8 (right panel) significantly increased when primary cells derived from the eight BrC patients were co-cultured with the primary monocytes from healthy donors. Three independent experiments were carried out and each point represents the mean of all determinations for each BrC primary isolate. Statistical significance ($p \leq 0.05$) is indicated with * and $p \leq 0.01$ with **.

showed high basal migratory properties, giving potent responses to MCP-1 (average number of migrating cells/field of 54,666.7). Although, we observed migration in response to GM-CSF and RANTES the number of migrating cells was not different than the control without chemoattractant (Figure 6B). U937 cells also exhibited migratory properties in the absence of chemoattractant (average number of migrating cells/field 10.7), although lesser than PM (18,666.7 cells). On the contrary, THP-1 cells were not intrinsically migratory in our experimental conditions even without Matrigel.

Interleukin-8 is another potent chemokine. Since IL-8 and MMPs are enriched upon co-culturing of the monocytes and the BrC cell lines, we decided to test whether IL-8 could facilitate invasion of the tumor cells. Figure 6C shows that the aggressive BrC cell lines responded to IL-8 (average number of invading cells/field were 11.5 for HS578T and 20.5 for MDA-MB-231 cells). We did not observe invasive properties in the absence of IL-8 or with the non-aggressive cell lines (Figure 6C). These data argue that the pro-inflammatory profile of the most aggressive BrC cells serve them to attract monocytes, and the BrC-monocyte association further enhances the tumor cell invasive properties.

**DISCUSSION**

Accurate prognosis and treatment of BrC remains a challenge, partly because most existing classifications of BrC are based on the tumor cell itself, and do not consider all the cell-to-cell interactions within the tumor stroma. In particular, TAMs are considered to be critical for tumor progression. A high density of TAMs indicates a poor prognosis (25–27). To better understand how the tumor cell communicates with recruited monocytes, we have co-cultivated early passages of BrC primary cell isolates and monocytes in a 3D system that recreates the cellular interactions with the ECM. We observed constitutively elevated levels of cytokines MCP-1, G-CSF, and RANTES in tumor cells, and of IL-1β, IL-8, MMP-1, MMP-2, and MMP-10 after co-culture. MCP-1 and G-CSF were potent chemoattractants of monocytes, while IL-8 was a potent inducer of invasion of the aggressive BrC cells (see Figure 7 for a depiction of a working model).

These cytokines are known to contribute toward the establishment of the tumor microenvironment. MCP-1, G-CSF, and RANTES are powerfull chemoattractants of monocytes and of other immune cells, particularly RANTES is a chemoattractant of neutrophils. MCP-1 also acts as an autocrine growth factor...
for neoplastic cells; promoting angiogenesis, invasion, and metastasis, contributing to tumor growth and dissemination (28, 29). Both MCP-1 and RANTES have minimal expression in noncancerous epithelial cells and increased expression in neoplastic cells. They contribute toward the establishment of an inflammatory microenvironment, which is paradoxically a potent suppressor of the cytotoxic T cell activity. MCP-1 and RANTES are direct inhibitors of cytotoxic T cells; and G-CSF is in addition associated with the recruitment of myeloid-derived suppressor cells (30, 31). IL-8 and IL-1β are also pro-inflammatory cytokines. IL-1β is produced primarily by activated macrophages and is involved in cell proliferation, differentiation, apoptosis, angiogenesis, and tumor invasion (32–35). IL-1β and EGF act synergistically and induce cell migration and invasion through increased expression and activity of MMPs (36).

Interleukin-8 and G-CSF are powerful stimulators of neutrophil generation, mobilization, activation, and survival (37–39). IL-8 induces multiple intracellular signaling pathways known to be constitutively active in tumor cells, neutrophils, and TAMs. IL-8 is also associated with angiogenesis, proliferation, tumor cell migration, and tumor progression to aggressive stages of the disease (37, 40–44). Fridlender and colleagues have postulated that neutrophils may have N1/N2 polarization states that mirror the M1/M2 phenotypes reported for macrophages; in which, the N2 and M2 types have pro-tumor activities (45). In a mouse model of BrC, Swierczak and colleagues found that blocking the CSF-1 (M-CSF)/CSF-1R interaction to prevent recruitment of circulating monocytes and M2 polarization increased the serum levels of G-CSF, leading to increased neutrophils in the primary tumor, and increased lung metastasis. When a G-CSF receptor antagonistic antibody was administered, it reversed the infiltration of neutrophils and reduced lung metastasis (46). In future studies, it will be interesting to further explore the possible collaboration between tumor cells, monocytes/macrophages and neutrophils; and to assess the capacity of these interactions to suppress T cell function.

In our model, cytokines that inhibit tumorigenesis were found to be suppressed. IL-12p70 and IFN-α2 were downregulated in all PC and commercial BrC cells. GM-CSF was downregulated in six PC, and in MCF-7 and T47D non-aggressive cells. These cytokines are known to have strong anti-tumor activity and are being used as immunoadjvants in anti-cancer vaccines. Recombinant human INF-α2b is part of an US Food and Drug Administration (FDA)-approved anti-tumor therapy (47–49).
IL-12p70 promotes the expansion and activation of cytotoxic CD8 T cells (50, 51) and has been used to stimulate immune anti-tumor activity in animal models (52). IL-12p70 has also been administered in clinical trials to increase the anti-tumor activity of anti-cancer vaccines (53–56). GM-CSF, a potent chemoattractant of neutrophils, monocytes, and lymphocytes (57), has also been used as adjuvant therapy in cancer vaccines. Interestingly, it was found that high GM-CSF doses favored pro-tumor activities, and low doses were an effective immune adjuvant (58).

One of the main mechanisms promoting tumor cell invasion and metastasis is the EMT (59). EMT-promoted cell invasion requires ECM degradation to facilitate cell migration. Mounting evidence support that both IL-1β and IL-8 promote EMT in tumor cells (28, 35, 60–63) and induce tumor cells, and other stromal cells, to secrete MMPs (61, 64–69). MMPs play a key role in the malignant progression of cancer. Their activity degrades and remodels the ECM, and liberates trapped cytokines and growth factor precursors (70–73). In this study, we observed that the levels of MMP-1, MMP-2, and MMP-10 significantly increased in co-cultures of tumor cells/monocytes, and we have previously shown that this correlates with increased collagen degradation (14). High levels of expression of MMP-1 have been associated with tumor growth, invasion and metastasis (74, 75), and MMP-1 levels have been proposed as a marker of poor prognosis in colorectal, breast, and lung cancers (74, 76, 77). MMP-1 has been associated with metastasis to brain in a BrC xenograft model (75). High levels of MMP-2 also correlate with tumor aggressiveness in various types of cancers (78–80). MMP-10 also catalyzes the conversion of pro-MMP-1 into its active form. MMP-10 expression has been associated with invasion and metastasis of pancreatic, cervical, bladder, colorectal, gastric, lung, and breast cancers (81–85).

In summary, cancer aggressiveness is strongly influenced by how tumor cells communicate with other cells within the tumor stroma. Considering that the intra- and inter-tumoral genetic heterogeneity have hampered the design of efficient therapeutic strategies, it is possible that the mechanisms that the tumor uses to communicate with its stroma are more limited and may provide better prognostic and therapeutic targets. Of interest is that the profile of cytokines enriched in tumor cells co-cultured with monocytes better corresponds to the one aided by M1 macrophages, rather than M2 macrophages. This is in agreement with our recent study in which we observed a mix of M1 and M2 types enriched upon monocytes co-culture with tumor cells (15). Interestingly, based on the morphology and behavior in co-culture with monocytes, the primary tumor cells more closely resemble aggressive cell lines. However, most of the patients were classified in clinical stage II and tumor grade II. In agreement, four PC exhibited EMT and invasive properties (Figure S1 in Supplementary Material) (86). We were not able to follow up the patients from which the primary tumor cells were expanded. In future studies it would be very interesting to analyze the nature of the tumor cells in culture (2D and 3D morphology, growth in mesenchymal medium), and their ability to instruct monocytes/macrophages to establish an inflammatory microenvironment rich in cytokines with pro-tumoral functions, and to compare these data with clinical staging and patient survival.

**AUTHOR CONTRIBUTIONS**

EF-P designed the study; GC-R and NE-S performed the experiments; EF-P, GC-R, NE-S, and AM interpreted the results; AM helped to recruit patients and analyzed and classified their type of tumors. EF-P, GC-R, and NE-S wrote the manuscript, and all the authors read it and comment it.

**ACKNOWLEDGMENTS**

The authors are grateful to Dr. Abigail Morales Sánchez for providing a critical review of the manuscript.
**FUNDING**

This work was supported by CONACYT FONSEC SSA/IMSS/ISSSTE Project No. 233061 to Ezequiel M. Fuentes-Panáná and by Fondo de Apoyo a la Investigación, Hospital Infantil de México Federico Gómez (project number HIM-2014-053). Nancy Adriana Espinoza-Sánchez is a doctoral student from Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM) and received fellowship 231663 from CONACYT. E-S NA, also acknowledge the financial support provided by the Mexican Institute of Social Security (IMSS).

**REFERENCES**

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer (2013). Available from: http://globocan.iarc.fr
2. Donepudi MS, Kandapalli K, Amos SJ, Venkateshnan P. Breast cancer statistics and markers. J Cancer Res Ther 2010;14(3):506–11. doi:10.1007/s10023-1482-200727
3. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res (2003) 5(1):31–6. doi:10.1186/bcr554
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646–74. doi:10.1016/j.cell.2011.02.013
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 4(1):71–8. doi:10.1038/nrc1256
6. Solinas G, Germaino G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol (2009) 86(5):1065–73. doi:10.1189/jlb.0609385
7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell (2010) 140(6):893–99. doi:10.1016/j.cell.2010.01.025
8. Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Cell (2010) 141(1):39–51. doi:10.1016/j.cell.2010.03.014
9. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in the tumor microenvironment. Immunol (2005) 175(1):342–9. doi:10.4049/immunol.175.1.342
10. Gordon S, Pludemann A, Martinez Estrada F. Macrophage heterogeneity in tissue: phenotypic diversity and functions. Immuno Rev (2014) 262(1):36–55. doi:10.1111/imr.12223
11. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 193(6):727–40. doi:10.1084/jem.193.6.727
12. Condeels J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 124(2):259–66. doi:10.1016/j.cell.2006.01.007
13. Qian BZ, Pollard JW. Macrophage diversity enhances tumour progression and metastasis. Cell (2010) 141(1):39–51. doi:10.1016/j.cell.2010.03.014
14. Chimal-Ramirez GK, Espinoza-Sanchez NA, Uttera-Barillas D, Benitez-Bribiesca L, Velazquez JR, Arriaga-Pizano LA, et al. MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness. Br Surg Res (2013) 2013:279505. doi:10.1155/2013/279505
15. Chimal-Ramirez GK, Espinoza-Sanchez NA, Chavez-Sanchez L, Arriaga-Pizano L, Fuentes-Panana EM. Monocyte differentiation towards tumor activity does not correlate with M1 or M2 phenotypes. J Immunol Res (2016) 2016:6031486. doi:10.1155/2016/6031486
16. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res (1990) 50(3):717–21.
17. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat (2004) 83(3):249–89. doi:10.1023/B:BREIA.0000014042.54925.cc
18. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat (2013) 142(2):237–55. doi:10.1007/s10549-013-2743-3
19. Ziegler E, Hansen MT, Haase M, Emons G, Grundkler C. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo. Breast Cancer Res Treat (2014) 148(2):269–77. doi:10.1007/s10549-014-3159-4
20. Hass R, Bartels H, Topley N, Hadam M, Kohler L, Goppelt-Strube M, et al. TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. Eur J Cell Biol (1989) 48(2):282–93.
21. Auwerx J. The human leukemia cell line, THP-1: a multifaceted model for the study of monocyte-macrophage differentiation. Expert Rev (1991) 1:22–31. doi:10.1615/BREIA.0000014042.54925.cc
22. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One (2010) 5(1):e8668. doi:10.1371/journal.pone.0008668
23. Minnafra L, Di Cara G, Albanese NN, Cancemi P. Proteomic differentiation pattern in the U937 cell line. Leuk Res (2011) 35(2):226–36. doi:10.1016/j.leukres.2010.07.040
24. Chimal-Ramirez GK, Espinoza-Sanchez NA, Fuentes-Panana EM. Promitotic activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J Oncol (2013) 2013:835956. doi:10.1155/2013/835956
25. Medrek C, Ponten F, Iirstrom K, Leanderson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer (2012) 12:306. doi:10.1186/1419-2407-12-306
26. Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat (2013) 12(3):259–67. doi:10.7785/tcrt.2012.500312
27. Sugimura K, Miyata H, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, et al. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol (2015) 111(6):752–9. doi:10.1002/jso.23881
28. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahosen N, Leider-Trejo L, Leibovich-Rivkin T, et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. Breast Cancer (2011) 11:130. doi:10.1186/1419-2407-11-130
29. Li M, Knight DA, Snyder LA, Smyth MJ, Stewart TJ. A role for CCL2 in both tumor progression and immunosurveillance. Oncimmunology (2013) 2(7):e25474. doi:10.4161/onci.25474
30. Weight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-suppressor cell-dependent mechanism. PLoS One (2011) 6(11):e27690. doi:10.1371/journal.pone.0027690

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00205/full#supplementary-material.

**FIGURE S1 | Primary breast cancer (BrC) cultures exhibit aggressive characteristics.** (A) Representative images of the immunofluorescence analysis of EMT markers E-cadherin and vimentin performed to four primary BrC cultures. (B) Representative images of the invasion assays and (C) graphical representations of the average integrated optical density (IOD) of the invading cells. Scale bars = 100 μM. Magnification 400x for panel (A) and 200x for panel (B). Cultures UIVC-IDC-1, UIVC-IDC-4, UIVC-IDC-5, and UIVC-IDC-11 senced before we could finish these analyses.
31. Agarwal S, Lakoma A, Chen Z, Hicks J, Metelitsa LS, Kim ES, et al. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation. *Cancer Res* (2015) 75(12):2566–79. doi:10.1158/0008-5472.CAN-14-2946

32. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. *Cancer Invest* (2000) 18(4):293–302. doi:10.3109/0735790009012171

33. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. *J Transl Med* (2006) 4:48. doi:10.1186/1477-5877-4-48

34. Ma L, Lan F, Zheng Z, Xie F, Wang L, Liu W, et al. Epidermal growth factor (EGF) and interleukin (IL)-1beta synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. *Mol Cancer* (2012) 11:79; doi:10.1186/1476-4598-11-79

35. Wanga DJ, Wilson C. The interleukin-8 pathway in cancer. *Clin Cancer Res* (2008) 14(12):6735–41. doi:10.1158/1078-0432.CCR-07-4843

36. Geering B, Stoeckle C, Conus S, Simon HU. Living and dying for inflammation: neutrophils, eosinophils, basophils. *Trends Immunol* (2013) 34(8):398–409. doi:10.1016/j.it.2013.04.002

37. Bendall LJ, Bradstock KE. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. *Cytokine Growth Factor Rev* (2014) 25(4):355–67. doi:10.1016/j.cytogfr.2014.07.011

38. Reed JR, Leon RP, Hall MK, Schwertfeger KL. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cytoxygenase-2 during early mammary tumour formation. *Breast Cancer Res* (2009) 11(2):R21. doi:10.1186/bcr2246

39. Bendall LJ, Bradstock KE. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. *Cytokine Growth Factor Rev* (2014) 25(4):355–67. doi:10.1016/j.cytogfr.2014.07.011

40. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer progression. *Blood* (2005) 105(11):21248–55. doi:10.1182/blood-2004-07-2672

41. Espinoza-Sánchez et al. Tumor Cell–Monocyte Communication CSF-1 signaling is blocked by targeting the G-CSF receptor. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. *Cancer Cell* (2014) 4:591–11. doi:10.1016/j.ccell.2013.06.001

42. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. *Expert Opin Ther Targets* (2013) 17(10):1345–55. doi:10.1517/14728222.2013.835398

43. Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. *Clin Cancer Res* (2007) 13(1):215–22. doi:10.1158/1078-0432.CCR-06-1450

44. Reed JR, Leon RP, Hall MK, Schwertfeger KL. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cytoxygenase-2 during early mammary tumour formation. *Breast Cancer Res* (2009) 11(2):R21. doi:10.1186/bcr2246

45. Li Y, Wang L, Pappan L, Gallher-Beckley A, Shi J. IL-1beta promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. *Mol Cancer* (2012) 11:87. doi:10.1186/1476-4598-11-87

46. Ma L, Lan F, Zheng Z, Xie F, Wang L, Liu W, et al. Epidermal growth factor (EGF) and interleukin (IL)-1beta synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. *Mol Cancer* (2012) 11:79; doi:10.1186/1476-4598-11-79

47. Wanga DJ, Wilson C. The interleukin-8 pathway in cancer. *Clin Cancer Res* (2008) 14(12):6735–41. doi:10.1158/1078-0432.CCR-07-4843

48. Geering B, Stoeckle C, Conus S, Simon HU. Living and dying for inflammation: neutrophils, eosinophils, basophils. *Trends Immunol* (2013) 34(8):398–409. doi:10.1016/j.it.2013.04.002

49. Bendall LJ, Bradstock KE. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. *Cytokine Growth Factor Rev* (2014) 25(4):355–67. doi:10.1016/j.cytogfr.2014.07.011

50. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. *Front Biosci* (2005) 10:853–65. doi:10.2741/1579

51. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granocytes. *Proc Natl Acad Sci U S A* (2010) 107(50):21248–55. doi:10.1073/pnas.1008551070

52. Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytli A, et al. Gr-1+CD11b+ myeloid cells tip the balance of immunogenic protection to tumor promotion in the premetastatic lung. *Cancer Res* (2010) 70(15):6139–49. doi:10.1158/0008-5472.CAN-10-0706

53. Sodvorov-Rakovic N, Milovanovic J. Interleukin-8 in breast cancer progression. *J Interferon Cytokine Res* (2013) 33(10):563–70. doi:10.1080/10780432.2013.812023

54. Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P, et al. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. *Sci Rep* (2014) 4:5911. doi:10.1038/srep05911

55. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. *Cancer Cell* (2009) 16(3):183–94. doi:10.1016/j.ccc.2009.06.017

56. Swierczek A, Cook AD, Lenzo JC, Restall CM, Doherty JP, Anderson RL, et al. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. *Cancer Immunol Res* (2014) 2(8):765–76. doi:10.1158/2326-6066.CIR-13-0190

57. Pichert G, Jost LM, Fierz W, Stahel RA. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. *Br J Cancer* (1991) 63(2):287–92. doi:10.1038/bjc.1991.67

58. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. *Oncologist* (2001) 6(1):34–53. doi:10.1634/theoncologist.6-1-34

59. Asmaning Ngurng R. Human interferon alpha-2b: a therapeutic protein for cancer treatment. *Scientifica (Cairo)* (2014) 2014:970315. doi:10.1155/2014/970315

60. Schmidt CS, Mescher MF. Adjuvant effect of IL-12: conversion of peptide anti-gen administration from tolerizing to immunizing for CD8+ T cells in vivo. *J Immunol* (1999) 163(5):2561–7.
NADPH oxidase 2-derived reactive oxygen species signals. *Mol Neurobiol* (2015) 52(1):303–17. doi:10.1007/s12053-014-8838-y

70. Hotary KB, Allen ED, Brooks PC, Datta NS, Long WR, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. *Cell* (2003) 114(1):33–45. doi:10.1016/S0092-8674(03)00513-0

71. Pardo A, Selman M. MMP-1: the elder of the family. *Int J Biochem Cell Biol* (2005) 37(2):283–8. doi:10.1016/j.biocel.2004.06.017

72. Iida J, McCarthy JB. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. *Melanoma Res* (2007) 17(4):205–13. doi:10.1097/CMR.0b013e3282a660ad

73. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. *Gene Dev* (2009) 23(16):1882–94. doi:10.1101/gad.1824809

74. Sauter W, Rosenberger A, Beckmann L, Kropp S, Timofeeva M, et al. Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. *Cancer Epidemiol Biomarkers Prev* (2008) 17(5):1127–35. doi:10.1158/1055-9965.EPI-07-2840

75. Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, et al. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. *BMC Cancer* (2012) 12:583. doi:10.1186/1471-2407-12-583

76. Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. *Nat Med* (2005) 11(5):481–3. doi:10.1038/nm1243

77. Poola I, DeWitty RL, Marshallack JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. *Nat Med* (2005) 11(5):481–3. doi:10.1038/nm1243

78. Schmalfeldt B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. *Prostate Cancer Prostatic Dis* (2003) 6(3):217–22. doi:10.1038/sj.pcd.4500657

79. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. *Clin Cancer Res* (2004) 10(22):7621–8. doi:10.1158/1078-0432.CCR-04-1061

80. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. *Clin Cancer Res* (2004) 10(22):7621–8. doi:10.1158/1078-0432.CCR-04-1061

81. Gill JH, Kirwan JG, Seargent JM, Martin SW, Tijani S, Anikin VA, et al. MMP-10 is overexpressed, proteolytically active, and a potential target for thera-

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Espinoza-Sánchez, Chimal-Ramírez, Mantilla and Fuentes-Panana. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.